Similar to heart failure patients, RAAS inhibitory medication was without statistically significant effects on serum ACE2 activity (Fig. 3D, Table 2), lung tissular ACE2 activity (Fig. 3E, Table 2) and ACE2 expression (Fig. 3F, Table 2) in patients with lung disease. This evidence concerns the gene ACE2 and heart failure.